DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1272 Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes.
N Engl J Med, 2009, 360:1646–1654.
Crandall JP, Knowler WC, Kahn SE, et al. The prevention of
type 2 diabetes. Nat Clin Pract Endocrinol Metab, 2008,
4:382–393.
Cryer PE. Glucose hoemostasis and hypoglycemia. In: Williams
Textbook of Endocrinology (Kronenberg HM, Melmed S,
Polonsky KS, Larsen PR, eds.), Philadelphia, Saunders
Elsevier, 2008.
Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management
of adult hypoglycemic disorders: An Endocrine
Society Clinical Practice Guideline. J Clin Endocrinol Metab,
2009, 94:709–728.
Das SK, Elbein SC. The genetic basis of type 2 diabetes.
Cellscience, 2006, 2:100–131.
DeFronzo RA, Goodman AM. The Multicenter Metformin Study
Group. Efficacy of metformin in patients with non-insulindependent
diabetes mellitus. N Engl J Med, 1995, 333: 541–549.
Diabetes Control Complications Trial Research Group. The
effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med, 1993, 329:977–986.
Donner TW, Flammer KM. Diabetes management in the hospital.
Med Clin North Am, 2008, 92:407–425, ix–x.
Doria A, Patti ME, Kahn CR. The emerging genetic architecture
of type 2 diabetes. Cell Metab, 2008, 8:186–200.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention
of macrovascular events in patients with type 2 diabetes
in the Proactive Study (Prospective Pioglitazone Clinical
Trial in Macrovascular Events): A randomised controlled trial.
Lancet, 2005, 366:1279–1289.
Drucker DJ. The biology of incretin hormones. Cell Metab,
2006, 3:153–165.
Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment
of type 2 diabetes: Preclinical biology and mechanisms of
action. Diabetes Care, 2007, 30:1335–1343.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and
vascular complications in veterans with type 2 diabetes. N Engl
J Med, 2009, 360:129–139.
Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of
mortality and adverse cardiovascular outcomes in type 2 diabetes:
A comparison of patients treated with sulfonylureas and
metformin. Diabetologia, 2006, 49:930–936.
Falciglia M. Causes and consequences of hyperglycemia in
critical illness. Curr Opin Clin Nutr Metab Care, 2007,
10:498–503.
Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional
glucose control in critically ill patients. N Engl J Med,
2009, 360:1283–1297.
Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on
the frequency of diabetes in patients with impaired glucose
tolerance or impaired fasting glucose: A randomised controlled
trial. Lancet, 2006, 368:1096–10105.
Grant RW, Moore AF, Florez JC. Genetic architecture of type 2
diabetes: Recent progress and clinical implications. Diabetes
Care, 2009, 32:1107–1114.
Heller SR. Minimizing hypoglycemia while maintaining
glycemic control in diabetes. Diabetes, 2008, 57: 3177–3183.
Herrington WG, Levy JB. Metformin: Effective and safe in renal
disease? Int Urol Nephrol, 2008, 40:411–417.
SECTION V
HORMONES AND HORMONE ANTAGONISTS
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of
intensive glucose control in type 2 diabetes. N Engl J Med,
2008, 359:1577–1589.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated
for cardiovascular outcomes in oral agent combination
therapy for type 2 diabetes (RECORD): A multicentre, randomised,
open-label trial. Lancet, 2009, 373: 2125–2135.
Huang S, Czech MP. The GLUT4 glucose transporter. Cell
Metab, 2007, 5:237–252.
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes:
Scientific review. JAMA, 2002, 287:360–372.
Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular
morbidity and mortality associated with metformin
use in subjects with type 2 diabetes. Diabet Med, 2005,
22:497–502.
Juvenile Diabetes Research Foundation Continuous Glucose
Monitoring Study Group. Continuous glucose monitoring and
intensive treatment of type 1 diabetes. N Engl J Med, 2008,
359:1464–1476.
Kahn SE. The relative contributions of insulin resistance and
beta-cell dysfunction to the pathophysiology of type 2 diabetes.
Diabetologia, 2003, 46:3–19.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of
rosiglitazone, metformin, or glyburide monotherapy. N Engl J
Med, 2006, 355:2427–2443.
Kamber N, Davis WA, Bruce DG, Davis TM. Metformin and
lactic acidosis in an Australian community setting: The
Fremantle Diabetes Study. Med J Aust, 2008, 188:446–449.
Kashi MR, Torres DM, Harrison SA. Current and emerging therapies
in nonalcoholic fatty liver disease. Semin Liver Dis,
2008, 28:396–406.
Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly
dosing of a long-acting release formulation of exenatide on
glucose control and body weight in subjects with type 2 diabetes.
Diabetes Care, 2007, 30:1487–1493.
Kitabchi AE, Umpierrez GE, Miles, JM, Fisher JN.
Hyperglycemic crises in adult patients with diabetes. Diabetes
Care, 2009, 32:1335–1343.
Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus.
Endocr Rev, 2008, 29:494–511.
Lalau JD, Race JM. Lactic acidosis in metformin therapy:
Searching for a link with metformin in reports of ‘metforminassociated
lactic acidosis.’ Diabetes Obes Metab, 2001,
3:195–201.
Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens
in type 2 diabetes mellitus: Systematic review and metaanalyses.
Diabetologia, 2009, 52:1990–2000.
Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones
and fracture risk. Arch Intern Med, 2008, 168: 820–825.
Moghissi ES, Korytkowski MT, DiNardo M, et al. American
Association of Clinical Endocrinologists and American
Diabetes Association Consensus Statement on Inpatient
Glycemic Control. Diabetes Care, 2009, 32:1119–1131.
Monami M, Lamanna C, Marchionni N, Mannucci E.
Comparison of different drugs as add-on treatments to metformin
in type 2 diabetes: A meta-analysis. Diabetes Res Clin
Pract, 2008, 79:196–203.
Murad MH, Coto-Yglesias F, Wang AT, et al. Clinical review:
Drug-induced hypoglycemia; a systematic review. J Clin
Endocrinol Metab, 2009, 94:741–745.